Gap Pharm-201: We need to establish an exploration formulary that identifies medications with maximal clinical benefit and minimal resource “costs” (mass, volume, etc.).
Last Published:  07/30/21 01:05:31 PM (Central)
Responsible Element: Exploration Medical Capability (ExMC)
Status: Open
Description

State of Knowledge: The current spaceflight formulary is based upon operational spaceflight experience and subject matter expert consultation.  These are the medications that are available to be used by astronauts on the International Space Station to treat the most common clinical conditions and those with significant consequences. As new evidence arises and novel risk assessment techniques are developed, future versions of an exploration formulary need to be developed using all of the best available evidence at any given time.


Approach: The optimal exploration formulary will treat those conditions that are expected to arise during deep space missions and will complement all the capabilities included in an exploration medical system. This exploration formulary will be developed using an iterative process based upon the best available evidence at the time. Currently, the evidence available is linked to exploration conditions lists which are subsequently mapped to medical capabilities and resources required (this includes pharmaceuticals. Future efforts will focus on using traceable and repeatable probabilistic risk assessment and trade space analysis processes that will utilize modeling to create more refined estimates for spaceflight conditions treated, capabilities and resources needed (including medications), and associated “costs” (mass, volume, etc.). This work is interconnected with other human system risks, primarily the Medical risk but also any other human system risk that is considering using pharmaceuticals as a mitigation strategy.


Target for Closure

Delivery of final exploration candidate formulary based upon trade space analysis that considers all human system risks

Mappings
Risk Risk of Ineffective or Toxic Medications During Long-Duration Exploration Spaceflight
You are here! Gap Pharm-201: We need to establish an exploration formulary that identifies medications with maximal clinical benefit and minimal resource “costs” (mass, volume, etc.).
Active
Completed
Planned-Funded

Multi-Disciplinary Research Plans

Documentation:
No Documentation Available